Institution
Georgetown University
Education•Washington D.C., District of Columbia, United States•
About: Georgetown University is a education organization based out in Washington D.C., District of Columbia, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 23377 authors who have published 43718 publications receiving 1748598 citations. The organization is also known as: GU & Georgetown.
Topics: Population, Cancer, Breast cancer, Health care, Politics
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, a qualitative evaluation of eight chemical methods commonly used to clean glass microscope slides in preparation for silanization was presented, and the mean contact angle of deionized water was measured before covalent attachment of (3-mercaptopropyl)triethoxysilane to assess the efficacy of each procedure.
367 citations
••
TL;DR: This study validates self-reports of two major health conditions, hypertension and diabetes, based on a recent survey in Taiwan (SEBAS 2000), and reveals that self- Reports vastly underestimate the prevalence of hypertension, but yield a reasonably accurate estimate ofThe prevalence of diabetes.
367 citations
••
University of Florida1, Commonwealth Scientific and Industrial Research Organisation2, University of Western Australia3, Imperial College London4, Lancaster University5, McGill University6, University of São Paulo7, University of Wisconsin-Madison8, Federal University of Pernambuco9, Georgetown University10, Rio de Janeiro State University11, University of Göttingen12, James Cook University13, George Mason University14, Michigan State University15
TL;DR: The authors argue that Fahrig's conclusions are drawn from a narrow and potentially biased subset of available evidence, which ignore much of the observational, experimental and theoretical evidence for negative effects of altered habitat configuration.
366 citations
••
Brigham and Women's Hospital1, Fred Hutchinson Cancer Research Center2, National Institutes of Health3, University of California, San Diego4, Los Angeles Biomedical Research Institute5, City of Hope National Medical Center6, Georgetown University7, MedStar Health8, University of Arizona9, HealthPartners10, University of Alabama at Birmingham11, Stanford University12, Ohio State University13, University of Tennessee Health Science Center14, George Washington University15, Wake Forest University16, University at Buffalo17
TL;DR: Among postmenopausal women, hormone therapy with C EE plus MPA or with CEE alone for a median of 7.2 years was not associated with risk of all-cause, cardiovascular, or cancer mortality during a cumulative follow-up of 18 years, without significant heterogeneity between trials.
Abstract: Importance Health outcomes from the Women’s Health Initiative Estrogen Plus Progestin and Estrogen-Alone Trials have been reported, but previous publications have generally not focused on all-cause and cause-specific mortality. Objective To examine total and cause-specific cumulative mortality, including during the intervention and extended postintervention follow-up, of the 2 Women’s Health Initiative hormone therapy trials. Design, Setting, and Participants Observational follow-up of US multiethnic postmenopausal women aged 50 to 79 years enrolled in 2 randomized clinical trials between 1993 and 1998 and followed up through December 31, 2014. Interventions Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo (n = 8102) for 5.6 years (median) or CEE alone (n = 5310) vs placebo (n = 5429) for 7.2 years (median). Main Outcomes and Measures All-cause mortality (primary outcome) and cause-specific mortality (cardiovascular disease mortality, cancer mortality, and other major causes of mortality) in the 2 trials pooled and in each trial individually, with prespecified analyses by 10-year age group based on age at time of randomization. Results Among 27 347 women who were randomized (baseline mean [SD] age, 63.4 [7.2] years; 80.6% white), mortality follow-up was available for more than 98%. During the cumulative 18-year follow-up, 7489 deaths occurred (1088 deaths during the intervention phase and 6401 deaths during postintervention follow-up). All-cause mortality was 27.1% in the hormone therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.03]) in the overall pooled cohort; with CEE plus MPA, the HR was 1.02 (95% CI, 0.96-1.08); and with CEE alone, the HR was 0.94 (95% CI, 0.88-1.01). In the pooled cohort for cardiovascular mortality, the HR was 1.00 (95% CI, 0.92-1.08 [8.9 % with hormone therapy vs 9.0% with placebo]); for total cancer mortality, the HR was 1.03 (95% CI, 0.95-1.12 [8.2 % with hormone therapy vs 8.0% with placebo]); and for other causes, the HR was 0.95 (95% CI, 0.88-1.02 [10.0% with hormone therapy vs 10.7% with placebo]), and results did not differ significantly between trials. When examined by 10-year age groups comparing younger women (aged 50-59 years) to older women (aged 70-79 years) in the pooled cohort, the ratio of nominal HRs for all-cause mortality was 0.61 (95% CI, 0.43-0.87) during the intervention phase and the ratio was 0.87 (95% CI, 0.76-1.00) during cumulative 18-year follow-up, without significant heterogeneity between trials. Conclusions and Relevance Among postmenopausal women, hormone therapy with CEE plus MPA for a median of 5.6 years or with CEE alone for a median of 7.2 years was not associated with risk of all-cause, cardiovascular, or cancer mortality during a cumulative follow-up of 18 years. Trial Registration clinicaltrials.gov Identifier:NCT00000611
366 citations
••
TL;DR: Galcanezumab 120-mg and 240-mg monthly injections provided clinical benefits and improved functioning, and the incidence rate of adverse events was low, demonstrating the favorable tolerability profile of galcaneZumab.
Abstract: Importance Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. Objective To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura. Design, Setting, and Participants The EVOLVE-1 (Evaluation of LY2951742 in the Prevention of Episodic Migraine 1) trial was a double-blind, randomized, placebo-controlled (January 11, 2016, to March 22, 2017) trial comparing galcanezumab (120 mg and 240 mg) vs placebo. Patients received treatments once monthly for 6 months (subcutaneous injection via prefilled syringe) and were followed up for 5 months after their last injection. It was a multicenter, clinic-based study involving 90 sites in North America. Participants in the study were adults (aged 18 to 65 years) with at least a 1-year history of migraine, 4 to 14 migraine headache days per month and a mean of at least 2 migraine attacks per month within the past 3 months, and were diagnosed prior to age 50 years. During the study, no other preventive medications were allowed. A total of 1671 patients were assessed; 809 did not meet study entry or baseline criteria, and 858 were included in the intent-to-treat population. Interventions Patients were randomized (2:1:1) to monthly placebo, galcanezumab, 120 mg, and galcanezumab, 240 mg. Main Outcomes and Measures The primary outcome was overall mean change from baseline in the number of monthly migraine headache days during the treatment period. Secondary measures included at least 50%, at least 75%, and 100% reduction in monthly migraine headache days, migraine headache days with acute medication use, and scores from the Migraine-Specific Quality of Life questionnaire, Patient Global Impression of Severity, and Migraine Disability Assessment. Treatment-emergent adverse events and serious adverse events were reported. Results Of the 1671 patients assessed, 858 (mean age, 40.7 years; 718 women [83.7%]) met study entry criteria and received at least 1 dose of investigational product. The primary objective was met for both galcanezumab doses; treatment with galcanezumab significantly reduced monthly migraine headache days (bothP Conclusions and Relevance Galcanezumab 120-mg and 240-mg monthly injections provided clinical benefits and improved functioning. The incidence rate of adverse events was low, demonstrating the favorable tolerability profile of galcanezumab. Trial Registration ClinicalTrials.gov Identifier:NCT02614183
366 citations
Authors
Showing all 23641 results
Name | H-index | Papers | Citations |
---|---|---|---|
Cyrus Cooper | 204 | 1869 | 206782 |
David Cella | 156 | 1258 | 106402 |
Carl H. June | 156 | 835 | 98904 |
Ichiro Kawachi | 149 | 1216 | 90282 |
Judy Garber | 147 | 756 | 79157 |
Bernard J. Gersh | 146 | 973 | 95875 |
Edward G. Lakatta | 146 | 858 | 88637 |
Eugene C. Butcher | 146 | 446 | 72849 |
Mark A. Rubin | 145 | 699 | 95640 |
Richard B. Devereux | 144 | 962 | 116403 |
Robert H. Purcell | 139 | 666 | 70366 |
Eric P. Winer | 139 | 751 | 71587 |
Richard L. Huganir | 137 | 425 | 61023 |
Rasmus Nielsen | 135 | 556 | 84898 |
Henry T. Lynch | 133 | 925 | 86270 |